Patients with a history of MI and high serum C-reactive protein (CRP) levels, who received a monoclonal antibody against IL-1β, canakinumab, had a significantly lower incidence of recurrent MI, stroke, or death from CVD compared to patients receiving placebo. Here, CRP is linked to myocardial infarction.